Rohinitib is a potent and specific eIF4A inhibitor. Rohinitib induces cell Significantly reduced the leukemia burden, circulating and BM leukemic human CD45+ cells. Dose-dependently prolonged the survival rate of mice.
[1]. Nishida Y, et alJ. Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML. Leukemia. 2021 Sep;35(9):2469-2481.
















